Menu

Press Releases

Date Summary View
Toggle Summary RedHill Biopharma Reports Third Quarter 2019 Financial Results and Operational Highlights
Key Highlights: U.S. FDA approval of Talicia ® for the treatment of Helicobacter pylori infection in adults   Strategic partnership with Cosmo Pharmaceuticals , including investment of $36.3 million and exclusive rights to commercialize Aemcolo ® in the U.S. ...
View HTML
Toggle Summary Dual-Listed RedHill Biopharma to Voluntarily Delist from Tel-Aviv Stock Exchange
TEL-AVIV, Israel and RALEIGH, N.C. , Nov. 15, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) ( Tel-Aviv Stock Exchange : RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the commercialization and development of proprietary drugs for ...
View HTML
Toggle Summary RedHill Biopharma to Host Third Quarter 2019 Financial Results Conference Call on November 19, 2019
TEL-AVIV, Israel and RALEIGH, N.C. , Nov. 13, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) ( Tel-Aviv Stock Exchange : RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the commercialization and development of proprietary drugs for ...
View HTML
Toggle Summary RedHill Biopharma Announces Publication of RHB-102 Gastroenteritis Phase 3 Study Results in JAMA
TEL-AVIV, Israel and RALEIGH, N.C. , Nov. 12, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) ( Tel-Aviv Stock Exchange : RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the commercialization and development of proprietary drugs for ...
View HTML
Toggle Summary RedHill Biopharma Announces FDA Approval of Talicia® for Treatment of H. pylori in Adults
RedHill plans to launch Talicia ® 1 in the U.S. in Q1/2020 for the treatment of H. pylori infection in adults, targeting more than two million patients estimated to be treated for  H. pylori infection annually Talicia ® is the first and only FDA approved rifabutin-based H. ...
View HTML
Toggle Summary RedHill Biopharma to Present at the BIO-Europe 2019 Conference
TEL-AVIV, Israel and RALEIGH, N.C. , Oct. 29, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) ( Tel-Aviv Stock Exchange : RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of clinical late-stage, ...
View HTML
Toggle Summary RedHill Biopharma to Present New Phase 3 Data on RHB-105 and RHB-104 at the American College of Gastroenterology 2019 Annual Meeting
TEL-AVIV, Israel and RALEIGH, N.C. , Oct. 28, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) ( Tel-Aviv Stock Exchange : RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of clinical late-stage, ...
View HTML
Toggle Summary RedHill Biopharma Announces $36 Million Strategic Investment by Cosmo Pharmaceuticals and U.S. Rights to Approved Travelers’ Diarrhea Drug AEMCOLO
TEL-AVIV, Israel and RALEIGH, N.C. , Oct. 18, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) ( Tel-Aviv Stock Exchange : RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of clinical late-stage, ...
View HTML
Toggle Summary RedHill Biopharma Sponsors No Stomach For Cancer’s Symposium Ahead of Stomach Cancer Awareness Month
TEL-AVIV, Israel and RALEIGH, N.C. , Oct. 16, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) ( Tel-Aviv Stock Exchange : RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of clinical late-stage, ...
View HTML
Toggle Summary RedHill Biopharma Announces Full Results from Positive MAP US Phase 3 Study and Supportive Top-Line Results from MAP US2 Open-Label Extension Study with RHB-104 in Crohn’s Disease
TEL-AVIV, Israel and RALEIGH, N.C. , Oct. 11, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) ( Tel-Aviv Stock Exchange : RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of clinical late-stage, ...
View HTML